What the lead investor is actually asking when they ask 'what's new'

At a glance

• “What’s new” from the lead investor is never small talk. It decodes to three real questions: does anything defend the current mark, is the next raise getting closer or further away, and do you know which decision you are avoiding.
• The strongest answer is a restated number with the decision attached. One line of restated ratio beats a paragraph of momentum language, every month, with every investor.
• The asymmetry compounds. Founders who answer with numbers get harder questions and more help. Founders who answer with narrative get softer questions and less time.

When the lead investor asks “what’s new,” they are asking three questions, and none of them is what’s new. The monthly check-in sounds casual because it is built to sound casual. A GP carrying fifteen to twenty-five positions cannot run a formal review of each one every month, so the casual question does the work of a formal review in four words. The founder who hears small talk answers with small talk. The founder who hears the real questions answers them, and the relationship changes shape from that call forward.

This is the decode. It is written for founders, and for the GPs reading over their shoulder who already know every word of it and wish their founders did too.

Why does a four-word question carry this much weight?

Because it is the cheapest diagnostic instrument the investor owns. The board meeting is quarterly, scripted, and rehearsed; the deck has been polished for two weeks before the GP sees it. The monthly check-in arrives unscripted, and the shape of the answer tells the investor more than the content does.

An answer built from numbers signals that the company knows its own position. An answer built from narrative (the pipeline is building, the team is energized, the new motion is showing promise) signals that the company is managing the investor’s mood rather than reporting its state. GPs have heard the narrative answer hundreds of times, and they have heard it most often from the companies that later stalled. They pattern-match on it whether they intend to or not.

What are the three real questions?

1. Has anything changed that defends the current mark? The GP is carrying your company at the last round’s valuation, and that mark gets discussed inside the fund whether you are in the room or not. Eighteen months past the raise, the internal question is whether the mark still reflects the company or just the round. “What’s new” is the GP collecting evidence, one month at a time. If revenue, retention, and burn are where they were last month, then nothing new defends the mark this month, and the GP just logged that, politely.

2. Is the next raise getting closer or further away? Every check-in is a data point on a single trendline: the distance between today’s numbers and a fundable story. Two new logos at a higher ACV move the raise closer. A flat quarter with rising burn moves it further away. The GP is not asking whether you are working hard; they assume you are. They are asking whether the gap is closing, at what rate, and whether the rate gets you there before the cash does not.

3. Do you know which decision you are avoiding? This is the question underneath the other two. A stalling company almost always has one material decision (a product line, a motion, a pricing structure, a senior hire) that everyone can see and nobody has put on a date. The GP wants to know whether you can name it. Founders who can name the decision they are avoiding are six months ahead of founders who cannot, even when both companies show the same numbers.

What does a good answer sound like?

Numbers, restated, with the decision attached. Not a paragraph; a line.

A weak answer: “Things are moving. Pipeline is the strongest it has been, the team is executing well, and we are seeing real pull on the enterprise side. Excited about the next couple of months.”

A strong answer: “NRR restated against paid accounts above $25K is 96%, down from 103% two quarters ago. The gap is concentrated in the mid-market cohort, and the keep-or-restructure decision on that motion is on the June board agenda with a one-pager.”

The weak answer takes thirty seconds and transmits nothing the GP can carry into their Monday partner meeting. The strong answer takes fifteen seconds and transmits three things: the company restates its own ratios instead of waiting to be asked, the company knows where the problem is concentrated, and the company has put the avoided decision on a date. One line of restated ratio beats a paragraph of momentum language because the ratio can be checked and the momentum cannot.

The restated part matters as much as the number. A blended NRR of 104% and a restated NRR of 96% can be the same company. The founder who volunteers the restated number before the GP digs for it converts a future credibility problem into a present deposit of trust.

What happens to founders who answer with numbers?

The asymmetry is the part most founders get backwards. Answering with numbers gets you harder questions. The GP who hears “96%, concentrated in mid-market, decision in June” will press on cohort math, on the cost of the restructure path, on what the board needs to see before it votes. That feels worse in the moment. It is the better outcome by a wide margin, because hard questions are how a GP spends attention, and attention is the scarcest resource in the fund. Founders who answer with numbers get harder questions and more help: intros, candidates, a straight read on how the next round will price.

Founders who answer with narrative get softer questions and less time. The GP stops probing, the calls get shorter, the monthly check-in quietly becomes quarterly. Softness from an investor is not kindness. It is triage. The portcos that get gentle questions are the ones the fund has quietly stopped defending. We wrote about this pattern from the other side of the table in The board question shift: when the questions get easier, the situation got worse.

So the play is simple to state. Answer the three real questions before they are asked. Lead with the restated number, name the concentration, name the decision and its date. Then let the hard questions come.

What is the Decisive Finance role in this?

The strong answer requires restated ratios and a named decision on hand, and most companies 18 months past a raise have neither. That is what the 14-day Decision Diagnostic produces: the three headline ratios restated against one explicit customer definition, the material decision named with a Keep/Kill/Restructure one-pager, and the recoverable value surfaced to fund the move. Guaranteed 3x your Diagnostic fee in recoverable value, in 14 days. Typical 5x to 10x. After the Diagnostic, “what’s new” has a fifteen-second answer every month, and it is an answer that defends the mark instead of dodging it.

Where to go from here

If the last three check-ins were answered with narrative, the next one is the place to change the pattern.

Read the guarantee Book the call

Related reading:

• The board question shift
• What GPs should ask at the next board meeting
• The one-page decision slide for boards